Download PDF
Zeitschrift für Phytotherapie 2006; 27(1): 47-50
DOI: 10.1055/s-2006-933357
Porträt einer Arzneipflanze

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Aktuelles über Passiflora incarnata

Passiflora incarnata - an updateLiselotte Krenn
Further Information

Publication History

Publication Date:
07 December 2006 (online)

    Permissions and Reprints

Zusammenfassung

Die Vielzahl wissenschaftlicher Publikationen, die in den letzten Jahren über Passionsblumenkraut und daraus hergestellte Extrakte erschienen sind, zeigt die anhaltende Bedeutung dieser Arzneipflanze. Neben zahlreichen pharmakologischen Untersuchungen - besonders einer indischen Forschergruppe - liegen auch erste klinische Studien mit Monopräparaten aus Passiflorae herba vor. Aus einer Reihe von In-vivo-Studien lassen sich dosisabhängige anxiolytische Effekte von Passiflora-Extrakten ableiten. In den ersten klinischen Studien an Patienten mit Angststörungen konnten mit Passiflora- Monopräparaten sehr gute Ergebnisse erzielt werden.

Summary

The number of papers dealing with Passionflower herb, which have been published during the last years, shows the continuous importance of this medicinal plant. Besides numerous pharmacological studies - mainly from a research group from India - first clinical studies with monopreparations of Passiflorae herba have been performed. Several pharmacological studies point to a dose-dependent anxiolytic activity of Passionflower extracts. In first clinical studies in patients with general anxiety disorders, who received Passionflower monopreparations, very good results were achieved.

Schlüsselwörter

Passionsblume - Passiflora incarnata L. - Inhaltsstoffe - Pharmakologie - klinische Studien

Key words

Passionflower - Passiflora incarnata L. - chemical constituents - pharmacological investigations - clinical studies

Literatur

  • 1 Akhondzadeh S, Kashani L, Mobaseri M. et al. . Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial.  J Clin Pharm Therap. 2001;  26 369-373
    CrossrefPubMedGoogle Scholar
  • 2 Akhondzadeh S, Naghavi HR, Vazirian M. et al. . Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam.  J Clin Pharm Therap. 2001;  26 363-367
    CrossrefPubMedGoogle Scholar
  • 3 Ansseau M. Evaluation des paramètres d'activite de gélules d'extrait sec de Passiflore selon un modèle »en etoiles«.  J Pharm Belg. 2004;  59 97-99
    PubMedGoogle Scholar
  • 4 Aoyagi N, Kimura R, Murata T. Studies on Passiflora incarnata dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol.  Chem Pharm Bull. 1974;  22 1008-1013
    CrossrefPubMedGoogle Scholar
  • 5 Brasseur T, Angenot L. Contribution à l'étude pharmacognostique de la Passiflore.  J Pharm Belg. 1984;  39 15-22
    PubMedGoogle Scholar
  • 6 Buchbauer G, Jirovetz L. Volatile constituents of the essential oil of Passiflora incarnata L.  J Essent Oil Res. 1992;  4 329-34
    PubMedGoogle Scholar
  • 7 Burkard W, Kopp B, Krenn L. et al. . Receptor binding studies in the CNS with extracts of Passiflora incarnata.  Pharm Pharmacol Lett. 1997;  7 25-26
    PubMedGoogle Scholar
  • 8 Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination.  Phytomedicine. 2005;  12 39-45
    CrossrefPubMedGoogle Scholar
  • 9 Dhawan K, Dhawan S, Chabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety from Passiflora incarnata L.: A not-habit forming anxiolytic.  J Pharm Pharmaceut Sci. 2003;  6 215-222
    PubMedGoogle Scholar
  • 10 Dhawan K, Dhawan S, Sharma A. Passiflora: a review update.  J Ethnopharmacol. 2004;  94 1-23
    CrossrefPubMedGoogle Scholar
  • 11 Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata.  Fitoterapia. 2001;  72 922-926
    CrossrefPubMedGoogle Scholar
  • 12 Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata L.  J Ethnopharmacol. 2001;  78 165-170
    CrossrefPubMedGoogle Scholar
  • 13 Dhawan K, Kumar S, Sharma A. Comparative biological activity study on Passiflora incarnata and P. edulis.  Fitoterapia. 2001;  72 698-702
    CrossrefPubMedGoogle Scholar
  • 14 Dhawan K, Kumar S, Sharma A. Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats.  J Med Food. 2002;  5 43-48
    CrossrefPubMedGoogle Scholar
  • 15 Dhawan K, Kumar S, Sharma A. Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata L. in mice.  Addiction Biology. 2002;  7 435-441
    CrossrefPubMedGoogle Scholar
  • 16 Dhawan K, Kumar S, Sharma A. Restoration of chronic delta9-THC-induced decline in sexuality in male rats by a novel benzoflavone moiety from Passiflora incarnata L.  BJP. 2002;  138 117-120
    CrossrefPubMedGoogle Scholar
  • 17 Dhawan K, Kumar S, Sharma A. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata L. in mice: a possible therapy for cannabinoid addiction.  J Pharm Pharmacol. 2002;  54 875-881
    CrossrefPubMedGoogle Scholar
  • 18 Dhawan K, Kumar S, Sharma A. Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety from Passiflora incarnata L. in mice.  J Ethnopharmacol. 2002;  81 239-244
    CrossrefPubMedGoogle Scholar
  • 19 Dhawan K, Kumar S, Sharma A. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata L.: A comment on medicinal plants' standardization.  J Alternat Complement Med. 2002;  8 283-291
    PubMedGoogle Scholar
  • 20 Dhawan K, Kumar S, Sharma A. Antiasthmatic activity of the methanol extract of leaves of Passiflora incarnata L.  Phytother Res. 2003;  17 821-822
    CrossrefPubMedGoogle Scholar
  • 21 Dhawan K, Kumar S, Sharma A. Aphrodisiac activity of methanol extract of leaves of Passiflora incarnata L. in mice.  Phytother Res. 2003;  17 401-403
    CrossrefPubMedGoogle Scholar
  • 22 Dhawan K, Sharma A. Antitussive activity of methanol extract of Passiflora incarnata L. leaves.  Fitoterapia. 2002;  73 397-399
    CrossrefPubMedGoogle Scholar
  • 23 Dhawan K, Sharma A. Prevention of chronic alcohol and nicotine-induced azospermia, sterility and decreased libido, by a novel tri-substituted benzoflavone moiety from Passiflora incarnata L. in healthy male rats.  Life Sciences. 2002;  71 3059-3069
    CrossrefPubMedGoogle Scholar
  • 24 ESCOP Monographs. 2nd Edition. European Scientific Cooperative on Phytotherapy; Stuttgart, New York: Thieme 2003: 359-364
    Google Scholar
  • 25 Kimura R, Matsui S, Ito S, Aimoto T, Murata T. Central depressant effects of maltol analogs in mice.  Chem Pharm Bull. 1980;  28 2570-2579
    CrossrefPubMedGoogle Scholar
  • 26 Kommission E des BGA .Monographie Passiflorae herba. BAnz Nr. 223 v. 30.11.1985 und Nr. 50. 1990
    Google Scholar
  • 27 Krenn L. Die Passionsblume (Passiflora incarnata L.) - ein bewährtes pflanzliches Sedativum.  Wien Med Wochenschr. 2002;  152 404-406
    CrossrefPubMedGoogle Scholar
  • 28 Löhdefink J, Kating H. Zur Frage des Vorkommens von Harmanalkaloiden in Passiflora-Arten.  Planta Med. 1974;  25 101-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lutomski J, Segiet E, Szpunar K, Grisse K. Die Bedeutung der Passionsblume in der Heilkunde.  Pharmazie in unserer Zeit. 1981;  10 45-49
    PubMedGoogle Scholar
  • 30 Meier B. Passiflorae herba - pharmazeutische Qualität.  Z Phytotherapie. 1995;  16 90-99
    PubMedGoogle Scholar
  • 31 Ministère des Affaires Sociales et de l'Emploide la France. . Spécialités Pharmaceutiques à Base de Plantes, Bulletin Officiel No 86/20 bis.  Übersetzung Pharm Ind. 1987;  49 1264-1274
    PubMedGoogle Scholar
  • 32 Rahman K, Krenn L, Kopp B. et al. . Isoscoparin-2„-O-glucoside from Passiflora incarnata.  Phytochemistry. 1997;  45 1093-1094
    CrossrefPubMedGoogle Scholar
  • 33 Rehwald A, Meier B, Sticher O. Qualitative and quantitative reversed-phase high-performance liquid chromatography of flavonoids in Passiflora incarnata L.  Pharm Acta Helv. 1994;  69 153-158
    PubMedGoogle Scholar
  • 34 Rehwald A, Sticher O, Meier B. Trace analysis of harman alkaloids in Passiflora incarnata by reversed-phase high performance liquid chromatography.  Phytochem Analysis. 1995;  6 96-100
    CrossrefPubMedGoogle Scholar
  • 35 Shinomiya K, Inoue T, Utsu Y. et al. . Hypnotic activities of Chamomile and Passiflora extracts in sleep-disturbed rats.  Biol Pharm Bull. 2005;  28 808-810
    CrossrefPubMedGoogle Scholar
  • 36 Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.  J Receptor Signal Transduct Res. 1999;  19 59-74
    PubMedGoogle Scholar
  • 37 Spencer KC, Seigler DS. Gynocardin from Passiflora.  Planta Med. 1984;  50 356-357
    PubMedGoogle Scholar
  • 38 Soulimani R, Younos C, Jarmouni S. et al. . Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse.  J Ethnopharmacol. 1997;  57 11-20
    CrossrefPubMedGoogle Scholar
  • 39 Tsuchiya H, Hayashi H, Sato M. et al. . Quantitative analysis of all types of β-carboline alkaloids in medicinal plants and dried edible plants by high perfomance liquid chromatography with selective fluorometric detection.  Phytochem Anal. 1999;  10 247-253
    CrossrefPubMedGoogle Scholar
  • 40 Tsuchiya H, Shimizu H, Iinuma M. Beta-carboline alkaloids in crude drugs.  Chem Pharm Bull. 1999;  47 440-443
    PubMedGoogle Scholar
  • 41 Weischer ML, Okpanyi SN. Pharmakologie eines pflanzlichen Schlafmittels.  Z Phytotherapie. 1994;  15 257-62
    PubMedGoogle Scholar

ao. Univ. Prof. Dr. Liselotte Krenn

Department für Pharmakognosie, Universität Wien, PharmaCenterVienna

Althanstraße 14

1090 Wien

Österreich

      >